IN CONTRAST TO WHAT IS OBSERVED in adults, transient nerve injury in neonates results in the long-term loss of motor neurons as well as extensive muscle atrophy (6, 23, 31, 46) . The extent of muscle atrophy appears to be different in subsets of hindlimb muscles 3-5 mo after neonatal sciatic axotomy, with anterior hindlimb muscles being more affected than posterior ones (25, 31) . In addition, nerve injury at postnatal day 5 (P5) results in the disappearance of fast, glycolytic muscle fibers that express myosin heavy chain IIB (MyHC IIB) in the extensor digitorum longus (EDL) muscle (23, 31) . Application of various muscle-derived neurotrophins [such as neurotrophin (NT)-3, NT-4/5, or brain-derived neurotrophic factor (BDNF)] or cytokines expressed by Schwann cells (CNTF) at the time of neonatal axotomy prevents, in part, the loss of motor neurons and the ensuing muscle atrophy (4, 18, 31, 37, 38, 46) . However, the specific rescue of MyHC IIB muscle fibers by these factors after neonatal nerve injury has so far been unsuccessful (31) .
BDNF has been shown to be an excellent candidate for the survival of both cultured motor neurons and injured motor neurons (4, 18, 19, 28, 33, 37, 46, 47, 49) . BDNF supports the survival of neurons through binding to its receptors, TrkB and/or p75, which leads to the activation of an intracellular phosphorylation cascade that culminates in specific transcriptional and translational events (1) . In this context, it is important to note that motor neurons innervating hindlimb muscles express both TrkB and p75 throughout postnatal development (13, 26) .
Newborn BDNF-null mice do not exhibit any loss in the number of motor neurons (5, 17, 20, 21) , suggesting that BDNF acts as a motor neuron survival factor during postnatal development and/or that other factors, such as NT-4/5, can functionally compensate for the lack of BDNF during embryogenesis. Interestingly, BDNF is expressed in embryonic and neonatal hindlimb muscles (13, 18) and is retrogradely transported to motor neuron cell bodies (7, 48) . Expression of BDNF is restricted to a subset of muscle fibers in embryonic hindlimb that may eventually express MyHC IIB in adults (13) . Furthermore, gastrocnemius muscles, which contain many MyHC IIB fibers, also express higher levels of BDNF during neonatal development compared with muscles lacking MyHC IIB fibers (32) . On the basis of these findings, we therefore hypothesized that BDNF acts as a target-derived neurotrophic factor for a subpopulation of motor neurons innervating MyHC IIB muscle fibers during neonatal development of the neuromuscular system.
In the present study, we have specifically tested this hypothesis. To determine the role of muscle-derived BDNF in the survival and maturation of a subpopulation of motor neurons innervating MyHC IIB fibers, we subjected newborn rats (P5) to sciatic nerve crush and then treated them with CNTF, BDNF, or a combination of both. Such combined administration of neurotrophins (i.e., CNTF ϩ BDNF) is known to have synergistic effects on cultured motor neurons (50) . Moreover, in our recent work (31), we treated newborn rats with CNTF ϩ NT-3 and with CNTF ϩ NT-4/5 after P5 neonatal nerve injury, which resulted in a greater recovery of muscle mass and motor units compared with single neurotrophin treatments, which were without effects (31) . We present here the results of a parallel series of experiments in which CNTF and BDNF were coadministered after P5 sciatic crush. We observed the survival of MyHC IIB fibers in EDL and TA muscles 3 mo after neonatal nerve crush with the combined administration of CNTF ϩ BDNF. In addition, we quantified the expression of BDNF in muscles containing relatively large proportions of MyHC IIB fibers (EDL) in the first 2 wk of life, during which motor neurons are susceptible to target removal (24) . We conclude that BDNF acts as a maturation factor for a subset of motor neurons innervating MyHC IIB-expressing fibers during neonatal development.
MATERIALS AND METHODS
Animals and surgical procedures. All animals were housed in the Animal Care Facility at the University of Ottawa and had unlimited access to food and water. All surgical procedures were approved by the University of Ottawa Animal Care and Use Committee. Rats were obtained from Charles River Laboratories (Quebec, Canada). Fiveday-old rat pups (P5) were subjected to sciatic nerve crush at the midthigh level as previously described (31) . A piece of gelfoam soaked in a solution of phosphate-buffered saline (PBS) containing CNTF (5 g), BDNF (2.5 g), or a combination of CNTF (5 g) and BDNF (2.5 g) was placed on the site of the crush. The animals were then injected daily with 0.005 ml/g body wt of PBS containing CNTF (0.3 g), BDNF (1.5 g), or a combination of CNTF (0.3 g) and BDNF (1.5 g) for 10 days after the crush. Neurotrophin doses were determined as previously described (31) . The administered BDNF doses were identical to those of NT-4/5 delivered in our previous study (31) . In our preliminary experiments, combined CNTF and BDNF doses higher than those delivered resulted in cachexia and death of the pups. Animals were housed in the Animal Care Facility for 3-5 mo until they were used in motor unit and muscle experimentation. Electrophysiological measurements of motor units in EDL muscles and immunohistochemisty of muscle sections have been described in detail elsewhere (31) . Immunohistochemistry of MyHC IIB fibers were performed using BF-F3 antibody (German Collection of Microorganisms and Cell Cultures, DSM, Germany), which is specific in detecting MyHC IIB. The contralateral control and experimental muscles were processed together for immunohistochemistry of embryonic (BF-45; German Collection of Microorganisms and Cell Cultures), neonatal (N1-551; Developmental Studies Hybridoma Bank, Iowa City, IA), and MyHC IIB isoforms. For some experiments, neonatal and adult rats were euthanized with a lethal dose of pentobarbital sodium (Somnotol; MTC Pharmaceuticals). EDL and soleus muscles, as well as the brain (hippocampus), were quickly excised and frozen in liquid nitrogen. The samples were kept at Ϫ80°C until use.
Enzyme-linked immunosorbent assay. The amount of BDNF was quantified from muscles and brain by using the Emax ImmunoAssay system (Promega, Madison, WI). Samples were homogenized in lysis buffer (1:1 vol/wt) containing 137 mM NaCl, 20 mM Tris ⅐ HCl (pH 8.0), 1% NP-40, 10% glycerol, 1 mM PMSF, 0.5 mM sodium vanadate, and one protease inhibitor cocktail tablet (Roche). Samples were then diluted with 4 vols of Dulbecco's phosphate-buffered saline, sonicated, and spun at 14,000 g for 30 min. The enzyme-linked immunosorbent assay (ELISA) procedure was performed according to the manufacturer's recommendations. Briefly, 96-well plates (MaxiSorp; NUNC) were coated overnight at 4°C with 1 g/ml monoclonal BDNF antibody diluted in carbonate coating buffer (pH 9.7). The plates were then blocked with 1ϫ block and sample buffer for 1 h. The plates were subsequently incubated for 2 h with samples and standards, washed, and incubated for another 2 h with a polyclonal BDNF antibody (0.5 g/ml). The plates were washed thoroughly and incubated with an anti-IgY horseradish peroxidase-conjugated antibody (1:200) for 1 h. Each reaction was developed using TMB One solution for 15 min. The reaction was stopped with 1 N HCl, and the sample absorbance was measured at 450 nm with an ELISA plate reader. Neonatal hippocampal extracts were used as a positive control for the ELISA experiments. We obtained BDNF concentrations of 200 -300 pg/ml or 1.05 Ϯ 0.10 pg/mg wet weight in neonatal hippocampal samples, which is in good agreement with previous findings (34) .
Quantitative RT-PCR. Total RNA was isolated from muscle and brain samples by using Trizol (Invitrogen Life Technologies, La Jolla, CA). The concentration of total RNA was determined using GeneQuant (Pharmacia). RNA samples were then diluted to 500 ng/l and used in a RT reaction containing 5 mM MgCl2, 1ϫ PCR buffer, 1 mM dNTP, 1 U/l RNase inhibitor, 5 U/l MuL V reverse transcriptase, and 2.5 M random hexamer. RT reactions were placed in a thermocycler at 42°C for 1 h, followed by 5 min at 99°C to deactivate the enzyme. With the use of BDNF forward (5Ј-CGACGTCCCTGGCTGACACTTTT-3Ј) and reverse (5Ј-AGTA-AGGGCCCGAACATACGATTGG-3Ј) primers, BDNF mRNA was amplified from the RT reactions (29) . In these experiments, the skeletal ␣-actin mRNA level, which was amplified using primers (forward, 5Ј-CGCGACATCAAAGAGAAGCT-3Ј; reverse, 5Ј-GGG-CGATGATCTTGATCTTC-3Ј), was used as internal control (22) . The PCR mix contained a final concentration of 2 mM MgCl 2, 1ϫ PCR buffer, 2.5 U/100 l AmpliTaq DNA polymerase (PerkinElmer), and 0.8 pmol/l primers. All PCR reactions were preheated to 94°C for 2 min. The PCR parameters were as follows: 94°C for 30 s, 60°C for 30 s, and 72°C for 30 s for the number of cycles indicated below.
In separate experiments, we ascertained that our PCR assays were within the linear range of amplification (see Fig. 6 ). To this end, we first reverse-transcribed total RNA and then performed several PCRs with 2-cycle increments spanning from 26 -40 and 8 -20 cycles for BDNF and ␣-actin, respectively. Subsequently, each designated PCR cycle sample was quantified on Vistra Green gels using a PhosphorImager and ImageQuant 5.1 (Molecular Dynamics, Sunnyvale, CA). By plotting cycle number vs. band intensity, we determined that 30 and 12 cycles were sufficient to obtain a reproducible signal within the linear range of PCR amplification for BDNF and ␣-actin, respectively (see Fig. 6 ). In these assays, the negative and positive samples, which consisted of RNA-free water and total brain RNA, respectively, were used in parallel in each RT-PCR experiment.
Statistical analysis. All values were compared using one-way ANOVA. Significant differences among three or more groups were subsequently determined using the LSD test. The level of significance was set at P Ͻ 0.05.
RESULTS
As previously reported, P5 rat pups were subjected to sciatic nerve crush and treated with a combination of neurotrophins (31) . Here, we report the results obtained from muscles of animals treated with CNTF, BDNF, or the combination CNTF ϩ BDNF after P5 sciatic nerve crush. As shown in Fig.  1A , we observed a significant (P Ͻ 0.05) recovery in the average muscle mass of EDL muscles with coadministration of CNTF ϩ BDNF as opposed to the untreated group or groups treated with CNTF or BDNF alone 3 mo after P5 sciatic crush. To determine whether there was also an improvement in the number of functional motor units in EDL muscles with the treatment of CNTF, BDNF, or CNTF ϩ BDNF, we performed a conventional ventral root-splitting technique as previously described (31) . The EDL muscles of animals treated with CNTF or CNTF ϩ BDNF contained a greater number of motor units compared with muscles from P5 sciatic crush or BDNFtreated animals 3 mo after neonatal nerve injury (Fig. 1B) .
Previously, we reported the disappearance of MyHC IIB fibers 3 mo after P5 sciatic crush in EDL muscles (31) . In the present study, we also failed to detect MyHC IIB fibers in the EDL muscles of animals that had undergone P5 sciatic crush and CNTF or BDNF treatment after P5 sciatic crush (Fig. 2 , 
B-D).
However, there were groups of fibers in the EDL muscles obtained from CNTF ϩ BDNF-treated animals that stained positively for MyHC IIB 3 mo after sciatic crush (Fig.  2, E and F) . Approximately 47% of the total number of fibers in a normal EDL muscle are MyHC IIB positive (Fig. 3) . Three months after P5 sciatic crush, EDL muscles contained essentially no MyHC IIB fibers (Fig. 3) . As shown in Fig. 3 , CNTF ϩ BDNF cotreatment led to a significant recovery in the number of MyHC IIB fibers in EDL muscles 3 mo after P5 sciatic crush. This partial recovery of MyHC IIB fibers in EDL muscles prompted us to investigate the recovery of these fibers in other hindlimb muscles after P5 sciatic crush with cotreatment of CNTF ϩ BDNF. The superficial area of a normal tibialis anterior (TA) muscle exclusively contained MyHC IIB fibers (Fig. 4A) . However, 3 mo after P5 sciatic crush, the MyHC IIB staining in TA muscle was observed only in small fibers that appeared necrotic (Fig 4B, arrowheads) . These small fibers did not stain positively with embryonic or neonatal MyHC antibodies (data not shown). With the administration of CNTF ϩ BDNF, MyHC IIB fibers were of normal size in the superficial area of TA muscle (Fig. 4, C-F) .
Because we only observed MyHC IIB fibers in EDL muscles of animals treated with CNTF ϩ BDNF after neonatal nerve injury, and because CNTF is not expressed in skeletal muscle (41), we hypothesized that BDNF is abundantly expressed in normal MyHC IIB fibers during development of the neuromuscular system to promote survival and maturation of a subset of motor neuron. Therefore, we quantified the amount of BDNF in muscles of similar sizes that either contained MyHC IIB fibers (EDL) or completely lacked these muscle fibers (soleus). As shown in Fig. 5A , soleus muscles of adults (1-2 mo old) contained 31% more BDNF than EDL muscles from the same animals. This trend was also observed in 3-mo-old animals (data not shown). Next, we determined the concentration of BDNF in muscles during the time when motor neurons innervating MyHC IIB fibers are susceptible to P5 sciatic nerve crush. To this end, we used EDL and soleus muscles from P5, P10, and P15 to determine the developmental pattern of expression of BDNF in different populations of muscle fibers. EDL muscles from neonates contained significantly (P Ͻ 0.05) more BDNF compared with soleus muscles (Fig. 5B) .
To begin understanding the levels at which BDNF expression is regulated in fast vs. slow muscles, we examined the relative abundance of BDNF mRNA in EDL and soleus muscles throughout development. We quantified the amount of BDNF mRNA by quantitative RT-PCR, using ␣-actin mRNA level as an internal standard (Fig. 6) . We observed that the levels of BDNF mRNA were ϳ42% higher (P Ͻ 0.05) in soleus vs. EDL muscles obtained from adult rats (Fig. 7A) . This difference in the expression level of BDNF transcripts is in good agreement with the protein concentration of BDNF obtained by ELISA (see above). To determine the level of BDNF mRNA in neonatal muscles, we quantified the relative abundance of BDNF transcripts in EDL and soleus muscles obtained from P3, P8, and P13 neonates. Interestingly, we observed that the levels of BDNF mRNA in EDL and soleus muscles in newborn animals were basically the same (Fig. 7B ) and, therefore, did not correlate with the protein concentration observed in these neonatal muscles.
DISCUSSION
Previously, we reported that anterior muscles from the hindlimb (EDL and TA) as well as their innervating motor neurons are most susceptible to P5 neonatal sciatic crush as opposed to their posterior counterparts (gastrocnemius and soleus) (31) . In this earlier work, we also showed that combined administration of CNTF ϩ NT-3 or CNTF and NT-4/5 rescued the number of motor units as well as the number of fibers in EDL muscles 3 mo after neonatal nerve injury (31) . However, the loss of MyHC IIB fibers in EDL was not prevented by the administration of CNTF ϩ NT-3 or CNTF ϩ NT-4/5, thereby indicating that these neurotrophins could not ensure the maturation of a subpopulation of motor neurons Fig. 1 . A: extensor digitorum longus (EDL) muscle mass from the postnatal day 5 (P5) sciatic crush side relative to the contralateral unoperated control side. Ciliary neurotrophic factor (CNTF; n ϭ 13) and brain-derived neurotrophic factor (BDNF; n ϭ 15) treatment did not enhance the recovery of EDL muscle mass 3 mo after P5 sciatic crush. Combined administration of CNTF ϩ BDNF (n ϭ 6) significantly enhanced the recovery of EDL muscle mass compared with the P5 sciatic crush group (n ϭ 7) (*P Ͻ 0.05); n ϭ no. of experiment samples/subjects. B: the number of motor units in the EDL of control (CTL; n ϭ 7), P5 sciatic crush (n ϭ 5), and CNTF (n ϭ 2)-, BDNF (n ϭ 2)-, and CNTF ϩ BDNF-treated (n ϭ 5) groups. EDL motor units were significantly rescued by application of CNTF or CNTF ϩ BDNF after P5 sciatic crush (*P Ͻ 0.05).
innervating MyHC IIB fibers 3-5 mo after P5 sciatic nerve crush. In the present study, using a complementary approach, we have demonstrated the survival of a substantial number of MyHC IIB muscle fibers in EDL and TA muscles with the administration of CNTF ϩ BDNF immediately after P5 sciatic nerve injury. We also have shown that expression of BDNF in EDL muscles is significantly greater than in soleus muscles of neonates. Together, these results are consistent with the notion that BDNF acts as a survival and maturation factor for motor neurons innervating MyHC IIB fibers during early postnatal development of the neuromuscular system. BDNF in developing MyHC IIB fibers. There is a distinct temporal and spatial pattern of BDNF expression in skeletal muscle during embryonic and early postnatal development (11, 13, 14, 32) . Griesbeck et al. (13) have demonstrated the expression of BDNF in developing muscle fibers adjacent to epidermal tissue of embryonic day 15 hindlimb. These developing muscle fibers are localized to the superficial areas of EDL and TA muscles, where MyHC IIB fibers are predominantly expressed in adult muscles. In the present study, we also detected, within the first 2 wk of life, a higher level of BDNF in EDL vs. soleus muscles. In accordance with our observations, Nagano and Suzuki (32) have also shown higher BDNF concentrations in the gastrocnemius muscle, which contains a high proportion of MyHC IIB fibers, compared with soleus muscles in neonatal animals. Collectively, these results demonstrate that there is preferential expression of BDNF in those developing muscle fibers that give rise to MyHC IIB fibers in adults.
The functional implication of the preferential expression of BDNF in MyHC IIB fibers during early postnatal development signifies its involvement in the electrophysiological modifica- tion of the motor neurons innervating developing MyHC IIB fibers. To date, studies that have examined the role of BDNF in modulating the electrophysiological properties of motor neurons have yielded contradictory findings (12, 35) . When BDNF is applied to neuromuscular contacts in adults, motor neurons innervating gastrocnemius muscle fibers mimic the electrical properties of those innervating soleus fibers by becoming more electrically excitable (12) . On the other hand, during neonatal development, BDNF decreases the excitability of motor neurons as monitored by changes in the monosynaptic sensory-tomotor inputs (35) . The synaptic inputs as well as motor neurons are in a dynamic state of modification and growth during the first week after birth (36) . Excitability modifications of motor neurons, which may be modulated in part by BDNF, are determined by the composition of synaptic inputs and ionic channels on motor neurons during neonatal development (35, 36) . In fact, BDNF upregulates the potassium conductance that is required for high-frequency firing of motor neurons inner- vating MyHC IIB fibers (27) . Therefore, it is conceivable that during early postnatal development, muscle-derived BDNF alters the electrical properties of motor neurons innervating MyHC IIB fibers toward those with lower excitability and a high-frequency phasic pattern of activation.
Expression of BDNF in muscles. There were similar levels of BDNF transcript in both EDL and soleus muscles from neonatal animals, whereas the amount of BDNF protein was clearly higher in EDL muscles. Because of this discordance between mRNA and protein levels, we speculate that BDNF synthesis is regulated by key translational events and/or that its secretion varies between subsets of EDL and soleus muscle fibers, hence leading to an accumulation in EDL muscles of neonates. Accumulation of BDNF in EDL muscles from neonates appears unlikely because neonatal motor neurons innervating EDL muscles require BDNF for their survival. In this context, it is important to note that the increase in BDNF protein levels seen in the hippocampus of newborns is not mirrored by an increase in the abundance of its transcripts (16) . Together, these results highlight the important contribution of translational mechanisms in regulating the expression of BDNF in skeletal muscles as well as in neurons.
In adult muscles, BDNF transcripts as well as protein levels were ϳ30 -40% higher in soleus than in EDL muscles, suggesting the involvement of pretranslational mechanisms in the regulation of BDNF expression. In this case, the higher levels of BDNF correlate with the activity of these muscles, because the total amount of neuromuscular activity is higher in adult soleus vs. EDL muscles (15) . In fact, the activity-dependent expression of BDNF has been well characterized in neurons both in vitro and in vivo (3). In neurons, higher activity triggers higher intracellular calcium levels, which in turn activate calcium-dependent transcriptional events (39, (43) (44) (45) . Given that the resting intracellular calcium levels and calcium entry are significantly higher in the more active skeletal muscles such as the soleus (9), these results strongly suggest that expression of BDNF in adult muscle is under the control of activity-regulated mechanisms that involve calcium signaling.
Effects of BDNF vs. NT-3 or NT-4/5. Studies performed with adult animals suggest a preferential role for other neurotrophins in the rescue of MyHC IIB fibers and their motor neurons. For example, Sterne et al. (40) have shown the rescue of MyHC IIB fibers in gastrocnemius muscles after treatment with NT-3 after axotomy in adults (40) . However, we did not observe any MyHC IIB fibers in EDL muscles from CNTF ϩ NT-3-treated animals 3 mo after neonatal sciatic crush, even though CNTF ϩ NT-3 was able to have beneficial effects on the number of motor units and total number of EDL muscle fibers (31) . The expression of NT-3 has been localized to most muscle fibers during embryogenesis, especially in those located in the deeper regions of the hindlimb such as in the soleus (13) . Therefore, we speculate that NT-3, which may have beneficial effects for MyHC IIB fibers in adults, does not act as a maturation factor for motor neurons innervating MyHC IIB fibers during early development of the neuromuscular system. Because BDNF and NT-4/5 bind with similar affinities to TrkB and/or p75, we expected to observe a similar rescue of MyHC IIB motor units in EDL muscles from animals subjected to neonatal nerve crush and treated with CNTF ϩ BDNF or CNTF ϩ NT-4/5. However, the EDL muscles from animals treated with CNTF ϩ NT-4/5 after neonatal sciatic nerve crush did not contain any MyHC IIB fibers (31) . Nonetheless, the administration of CNTF ϩ NT-4/5 was more effective in rescuing motor units of EDL after neonatal nerve injury (31) . During embryogenesis, the expression of NT-4/5 has been localized to the epidermal tissue, whereas BDNF transcripts are found in developing muscle fibers of the hindlimb (13) . The expression of BDNF and NT-4/5 is activity dependent and has been localized to slow muscle fibers in adult soleus muscles (10) . Also, NT-4/5 and BDNF have been shown to shift the MyHC expression profile of muscle fibers and electrophysiological properties of motor neurons, respectively, toward a slower phenotype (2, 12) . These data suggest that although BDNF and NT-4/5 have redundant roles in adults, they may have different functions during embryogenesis and early postnatal development. In fact, replacing the BDNF locus with NT-4/5 results in the rescue of many BDNF-null sensory deficiencies but suggests different functions through different variants of TrkB (8) . Naturally occurring splice variants of TrkB have different affinities for BDNF and NT-4/5 (42) . Thus it is plausible to consider the existence of different intracellular signals initiated from the splice variants of TrkB, leading to different cellular functions depending on the presence of BDNF or NT-4/5 during motor or sensory neuronal development (30) .
